ATE339449T1 - Anthrax-spezifisches antigen, impfstoffe die das antigen enthalten, anthrax-spezifische antikörper,und deren verwendungen - Google Patents

Anthrax-spezifisches antigen, impfstoffe die das antigen enthalten, anthrax-spezifische antikörper,und deren verwendungen

Info

Publication number
ATE339449T1
ATE339449T1 AT01932697T AT01932697T ATE339449T1 AT E339449 T1 ATE339449 T1 AT E339449T1 AT 01932697 T AT01932697 T AT 01932697T AT 01932697 T AT01932697 T AT 01932697T AT E339449 T1 ATE339449 T1 AT E339449T1
Authority
AT
Austria
Prior art keywords
antigen
spores
anthracis
anthrax
antibodies
Prior art date
Application number
AT01932697T
Other languages
English (en)
Inventor
Beverly L Mangold
Jennifer L Aldrich
Thomas W O'brien
Original Assignee
Tetracore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetracore Inc filed Critical Tetracore Inc
Application granted granted Critical
Publication of ATE339449T1 publication Critical patent/ATE339449T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01932697T 2000-04-28 2001-04-30 Anthrax-spezifisches antigen, impfstoffe die das antigen enthalten, anthrax-spezifische antikörper,und deren verwendungen ATE339449T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20050500P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
ATE339449T1 true ATE339449T1 (de) 2006-10-15

Family

ID=22742002

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01932697T ATE339449T1 (de) 2000-04-28 2001-04-30 Anthrax-spezifisches antigen, impfstoffe die das antigen enthalten, anthrax-spezifische antikörper,und deren verwendungen

Country Status (7)

Country Link
US (2) US7618783B2 (de)
EP (1) EP1280828B1 (de)
AT (1) ATE339449T1 (de)
AU (1) AU2001259204A1 (de)
CA (1) CA2420287A1 (de)
DE (1) DE60123036T2 (de)
WO (1) WO2001083561A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI253471B (en) 2001-01-31 2006-04-21 Food Industry Res & Dev Inst Method for rapid identification of bacillus cereus
US7262019B2 (en) * 2001-05-03 2007-08-28 Immunetics, Inc. System and methods for detection of Bacillus anthracis related analytes in biological fluids
US7105311B2 (en) * 2001-05-03 2006-09-12 Immunetics, Inc. Systems and methods for detection of analytes in biological fluids
ATE371015T1 (de) 2001-11-30 2007-09-15 California Inst Of Techn Verbesserung in einem verfahren zur quantifizierung bakterieller endosporen mittels lanthaniddipicolinat-lumineszenz
GB0129776D0 (en) * 2001-12-13 2002-01-30 Sec Dep For Environment Food & Assay device and method
US6927068B2 (en) * 2002-01-30 2005-08-09 The United States Of America As Represented By The Secretary Of The Navy Rapid and non-invasive method to evaluate immunization status of a patient
AU2003208933A1 (en) 2002-02-01 2003-09-02 California Institute Of Technology Methods and apparatus for assays of bacterial spores
WO2003087822A2 (en) * 2002-04-10 2003-10-23 Response Biomedical Corporation Sensitive immunochromatographic assay
US7175992B2 (en) * 2002-04-10 2007-02-13 Response Biomedical Corporation Sensitive immunochromatographic assay
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US7611862B2 (en) 2004-11-12 2009-11-03 California Institute Of Technology Method and apparatus for detecting and quantifying bacterial spores on a surface
US7563615B2 (en) 2005-04-15 2009-07-21 California Institute Of Technology Apparatus and method for automated monitoring of airborne bacterial spores
US7608419B2 (en) 2003-11-13 2009-10-27 California Institute Of Technology Method and apparatus for detecting and quantifying bacterial spores on a surface
EP1616023A4 (de) * 2003-03-21 2011-12-21 Government Of The Usa Represented By The Dept Of Health And Human Services Ct S For Disease Control Auffinden des nutzbaren teils einer sigmoiden kurve
MXPA05012571A (es) * 2003-05-21 2006-02-08 Medarex Inc Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
US7928204B2 (en) * 2004-05-12 2011-04-19 Tetracore, Inc. Spore specific antigen
WO2006033675A2 (en) * 2004-05-12 2006-03-30 Tetracore, Inc. Bacillus anthracis spore specific antobodies
US20060115908A1 (en) * 2004-11-30 2006-06-01 Tetracore, Inc. Multiplexed analyses of contaminant-laden gas in a particle impact collector
BRPI0613111A2 (pt) 2005-07-08 2010-12-21 Univ Mexico Nacional Autonoma proteìnas bacterianas com atividade pesticida
GB0514319D0 (en) * 2005-07-13 2006-06-14 Secr Defence Antibodies for anthrax
EP2021021A2 (de) * 2006-05-12 2009-02-11 Oklahoma Medical Research Foundation Anthrax-zusammensetzungen und verfahren zu ihrer herstellung und anwendung
EP2264143A3 (de) 2006-06-30 2012-03-07 University Of Georgia Research Foundation, Inc. Anthrax-Kohlenhydrate sowie Synthese und Verwendungen davon
US8420607B2 (en) * 2006-06-30 2013-04-16 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates, synthesis and uses thereof
US7875433B2 (en) * 2007-02-26 2011-01-25 Response Biomedical Corporation Comparative multiple analyte assay
US7935345B2 (en) 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
US8343495B2 (en) * 2009-01-10 2013-01-01 Auburn University Equine antibodies against Bacillus anthracis for passive immunization and treatment
US9857370B2 (en) * 2013-07-22 2018-01-02 National Technology & Engineering Solutions Of Sandia, Llc Amplification of biological targets via on-chip culture for biosensing
CN105092853A (zh) * 2014-05-06 2015-11-25 中国检验检疫科学研究院 检测多种Bt蛋白的液相芯片及检测方法
CN105203766B (zh) * 2015-09-29 2017-01-11 河南省科学院生物研究所有限责任公司 一种致病性小肠结肠炎耶尔森氏菌测试条制备方法
CN110498854B (zh) * 2019-09-28 2021-01-29 中国人民解放军陆军军医大学 一种抗金黄色葡萄球菌肠毒素b的抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426470D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
US5840312A (en) 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
US5895922A (en) 1996-03-19 1999-04-20 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Fluorescent biological particle detection system
US6913756B1 (en) 1998-04-29 2005-07-05 The Uab Research Foundation Monoclonal antibodies specific for anthrax and peptides derived from the antibodies thereof
WO1999064863A1 (en) * 1998-06-12 1999-12-16 New Horizons Diagnostics, Inc. Colloidal colorimetric flow through and lateral flow assays utilizing soluble submicron particles
CA2396696A1 (en) 2000-01-06 2001-07-12 Biosite Diagnostics, Inc. Assays for detection of bacillus anthracis

Also Published As

Publication number Publication date
US20110200614A1 (en) 2011-08-18
DE60123036T2 (de) 2007-04-05
US20020082386A1 (en) 2002-06-27
WO2001083561A3 (en) 2002-05-30
CA2420287A1 (en) 2001-11-08
AU2001259204A1 (en) 2001-11-12
US7618783B2 (en) 2009-11-17
EP1280828A2 (de) 2003-02-05
EP1280828B1 (de) 2006-09-13
WO2001083561A2 (en) 2001-11-08
DE60123036D1 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
ATE339449T1 (de) Anthrax-spezifisches antigen, impfstoffe die das antigen enthalten, anthrax-spezifische antikörper,und deren verwendungen
Weichhart et al. Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro
Boyle Bacterial Immunoglobulin–Binding Proteins: Applications in Immunotechnology
WO2001049823A3 (en) Assays for detection of bacillus anthracis
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
MX2020000435A (es) Anticuerpos anti-cd166 y usos de estos.
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
CY1109725T1 (el) Ειδικες δεσμευομενες πρωτεϊνες και χρησεις αυτων
DE69735294D1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
NO981745L (no) Monoklonalt antistoff BR110 og anvendelse av dette
DE60132770D1 (de) Chimäre humane papillomavirus (hpv) l1 moleküle und deren verwendungen
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
DE602005022589D1 (de) Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2
Mdluli et al. Gold nanoparticle based Tuberculosis immunochromatographic assay: The quantitative ESE Quanti analysis of the intensity of test and control lines
Frisk et al. Self-assembled peptide monolayers as a toxin sensing mechanism within arrayed microchannels
WO2001066568A3 (en) Use of recombinant antigens to determine the immune status of an animal
Oehmcke et al. Function of the fibronectin-binding serum opacity factor of Streptococcus pyogenes in adherence to epithelial cells
Maňásková et al. Rapid detection and semi-quantification of IgG-accessible Staphylococcus aureus surface-associated antigens using a multiplex competitive Luminex assay
Kumar et al. Immune responses to Mycobacterium tuberculosis membrane-associated antigens including alpha crystallin can potentially discriminate between latent infection and active tuberculosis disease
Feikin et al. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults
TW200740840A (en) Diagnostic test kits
WO2003106649A3 (en) CONJUGATE TEST AND USES THEREOF
Atanackovic et al. Deep dissection of the antiviral immune profile of patients with COVID-19
WO2007001737A3 (en) Methods and compositions for detecting herpes simplex virus type 2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties